Evidence map›Paper›PMID 42293769›Full record

ArticleDiscovery immunology2026

Using peptide-exchange systems to interrogate peptide-specific KIR binding to HLA Class I.

Tanusya M Murali, Beining Li, Emery Hoos, Lucy Collinson, Eric O Long, Omer Dushek, Tim Elliott, Malcolm J W Sim

Abstract read
In one paragraph

Article in Discovery immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Tanusya M MuraliCentre for Immuno-Oncology, Nuffield Department of Medicine, University of Oxford, Oxford OX3 7DQ, UK.
Beining LiCentre for Immuno-Oncology, Nuffield Department of Medicine, University of Oxford, Oxford OX3 7DQ, UK.
Emery HoosCentre for Immuno-Oncology, Nuffield Department of Medicine, University of Oxford, Oxford OX3 7DQ, UK.
Lucy CollinsonCentre for Immuno-Oncology, Nuffield Department of Medicine, University of Oxford, Oxford OX3 7DQ, UK.
Eric O LongLaboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, NIH, Rockville, MD 20886, USA.
Omer DushekSir William Dunn School of Pathology, University of Oxford, Oxford, OX1 3RE, UK.ORCID https://orcid.org/0000-0001-5847-5226
Tim ElliottCentre for Immuno-Oncology, Nuffield Department of Medicine, University of Oxford, Oxford OX3 7DQ, UK.
Malcolm J W SimCentre for Immuno-Oncology, Nuffield Department of Medicine, University of Oxford, Oxford OX3 7DQ, UK.ORCID https://orcid.org/0000-0003-3407-9661

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The killer-cell immunoglobulin-like receptors (KIR) are a family of activating and inhibitory Class I human leukocyte antigen (HLA-I) binding receptors expressed on natural killer (NK) cells and subsets of T cells. The KIR detect HLA-I molecules in a peptide-dependent manner, with some KIR displaying exquisite peptide specificity. Studying peptide recognition by KIR often uses TAP-deficient cell lines expressing single HLA-I alleles, which are heterogenous and time consuming to generate. Here, we established an alternative approach using peptide-exchange technologies hitherto developed for studying T cell recognition of HLA-I. Methods: We tested two methods; dipeptide-mediated peptide exchange and "open-HLA-I", HLA-I molecules consisting of heavy chain-β Results: We demonstrated the fidelity of this system with peptides of known KIR specificity bound to HLA-C*05:01. We then screened a peptide library to identify novel strong KIR2DS4 binding peptides presented by HLA-C*04:01. Peptide-exchanged HLA-C was functionally competent, promoting activation of KIR2DS4+ NK cells and inhibiting activation of KIR2DL1+ NK cells. Conclusion: Together, we show that peptide-exchangeable HLA-I molecules are ligands for KIR, presenting a flexible, efficient system for examining the peptide sequence dependent recognition of HLA-I by KIR.

Indexed as

HLA-IKIRpeptidepeptide-exchange

Identifiers

PMID42293769
PMCPMC13262528

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.